335 related articles for article (PubMed ID: 21504247)
21. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
22. Comparison of filgrastim and lenograstim in pediatric solid tumors.
Sarı N; Dalva K; Ilhan IE
Pediatr Hematol Oncol; 2013 Oct; 30(7):655-61. PubMed ID: 24050764
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
24. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
[TBL] [Abstract][Full Text] [Related]
25. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
26. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
Johnston E; Crawford J; Blackwell S; Bjurstrom T; Lockbaum P; Roskos L; Yang BB; Gardner S; Miller-Messana MA; Shoemaker D; Garst J; Schwab G
J Clin Oncol; 2000 Jul; 18(13):2522-8. PubMed ID: 10893282
[TBL] [Abstract][Full Text] [Related]
27. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
28. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.
Paul M; Ram R; Kugler E; Farbman L; Peck A; Leibovici L; Lahav M; Yeshurun M; Shpilberg O; Herscovici C; Wolach O; Itchaki G; Bar-Natan M; Vidal L; Gafter-Gvili A; Raanani P
Am J Hematol; 2014 Mar; 89(3):243-8. PubMed ID: 24178750
[TBL] [Abstract][Full Text] [Related]
30. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
31. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group.
Donadieu J; Boutard P; Bernatowska E; Tchernia G; Couillaud G; Philippe N; Le Gall E
Eur J Pediatr; 1997 Sep; 156(9):693-700. PubMed ID: 9296532
[TBL] [Abstract][Full Text] [Related]
32. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
Gisselbrecht C; Prentice HG; Bacigalupo A; Biron P; Milpied N; Rubie H; Cunningham D; Legros M; Pico JL; Linch DC
Lancet; 1994 Mar; 343(8899):696-700. PubMed ID: 7510813
[TBL] [Abstract][Full Text] [Related]
33. Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor.
Carulli G; Mattii L; Azzarà A; Brizzi S; Galimberti S; Zucca A; Benedetti E; Petrini M
Am J Hematol; 2006 May; 81(5):318-23. PubMed ID: 16628714
[TBL] [Abstract][Full Text] [Related]
34. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
35. Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.
Ria R; Reale A; Melaccio A; Racanelli V; Dammacco F; Vacca A
Clin Exp Med; 2015 May; 15(2):145-50. PubMed ID: 24722996
[TBL] [Abstract][Full Text] [Related]
36. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
37. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
38. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.
Juan O; Campos JM; Carañana V; Sanchez JJ; Casañ R; Alberola V
Support Care Cancer; 2001 Jun; 9(4):241-6. PubMed ID: 11430419
[TBL] [Abstract][Full Text] [Related]
39. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH
J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465
[TBL] [Abstract][Full Text] [Related]
40. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
